Retrophin, Inc. (RTRX) Shares Sold by Metropolitan Life Insurance Co. NY
Metropolitan Life Insurance Co. NY cut its position in shares of Retrophin, Inc. (NASDAQ:RTRX) by 2.8% during the first quarter, Holdings Channel reports. The institutional investor owned 24,503 shares of the biopharmaceutical company’s stock after selling 718 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Retrophin were worth $452,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in RTRX. Weiss Multi Strategy Advisers LLC bought a new position in shares of Retrophin during the first quarter worth about $185,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Retrophin during the first quarter worth about $219,000. Highbridge Capital Management LLC bought a new position in shares of Retrophin during the fourth quarter worth about $243,000. American International Group Inc. increased its position in shares of Retrophin by 7.1% in the first quarter. American International Group Inc. now owns 22,300 shares of the biopharmaceutical company’s stock worth $412,000 after buying an additional 1,475 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Retrophin during the fourth quarter worth about $782,000.
Retrophin, Inc. (NASDAQ:RTRX) traded up 1.62% during trading on Tuesday, reaching $22.62. 107,431 shares of the company’s stock traded hands. Retrophin, Inc. has a 12 month low of $15.55 and a 12 month high of $24.57. The company has a 50-day moving average of $19.96 and a 200 day moving average of $19.06. The stock’s market capitalization is $868.27 million.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.10. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The company had revenue of $38.80 million during the quarter, compared to analyst estimates of $37.36 million. During the same period in the previous year, the company earned $0.07 EPS. The business’s revenue for the quarter was up 16.5% compared to the same quarter last year. On average, equities research analysts expect that Retrophin, Inc. will post ($1.11) earnings per share for the current fiscal year.
A number of equities analysts have recently issued reports on the stock. ValuEngine upgraded shares of Retrophin from a “sell” rating to a “hold” rating in a report on Friday, August 4th. TheStreet upgraded shares of Retrophin from a “d” rating to a “c-” rating in a report on Friday, May 12th. Finally, Zacks Investment Research downgraded shares of Retrophin from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 3rd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Retrophin presently has an average rating of “Buy” and an average price target of $32.25.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin, Inc. (NASDAQ:RTRX).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.